Corlentor

Nazione: Unione Europea

Lingua: inglese

Fonte: EMA (European Medicines Agency)

Compra

Foglio illustrativo Foglio illustrativo (PIL)
12-10-2021
Scheda tecnica Scheda tecnica (SPC)
12-10-2021

Principio attivo:

ivabradine hydrochloride

Commercializzato da:

Les Laboratoires Servier

Codice ATC:

C01EB17

INN (Nome Internazionale):

ivabradine

Gruppo terapeutico:

CARDIAC THERAPY

Area terapeutica:

Angina Pectoris; Heart Failure

Indicazioni terapeutiche:

Symptomatic treatment of chronic stable angina pectorisIvabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ≥ 70 bpm. Ivabradine is indicated:in adults unable to tolerate or with a contraindication to the use of beta-blockersor in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose.Treatment of chronic heart failureIvabradine is indicated in chronic heart failure NYHA II to IV class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.

Dettagli prodotto:

Revision: 26

Stato dell'autorizzazione:

Authorised

Data dell'autorizzazione:

2005-10-25

Foglio illustrativo

                                28
B. PACKAGE LEAFLET
29
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
CORLENTOR 5 MG FILM-COATED TABLETS
CORLENTOR 7.5 MG FILM-COATED TABLETS
ivabradine
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
:
1.
What Corlentor is and what it is used for
2.
What you need to know before you take Corlentor
3.
How to take Corlentor
4.
Possible side effects
5
How to store Corlentor
6.
Contents of the pack and other information
1.
WHAT CORLENTOR IS AND WHAT IT IS USED FOR
Corlentor (ivabradine) is a heart medicine used to treat:
-
Symptomatic stable angina pectoris (which causes chest pain) in adult
patients whose heart rate is
over or equal to 70 beats per minute.
It is used in adult patients who do not tolerate or cannot take
heart medicines called beta-blockers. It is also used in combination
with beta-blockers in adult
patients whose condition is not fully controlled with a beta-blocker.
-
Chronic heart failure in adult patients whose heart rate is over or
equal to 75 beats per minute. It
is used in combination with standard therapy, including beta-blocker
therapy or when beta-
blockers are contraindicated or not tolerated.
About stable angina pectoris (usually referred to as “angina”):
Stable angina is a heart disease which happens when the heart does not
receive enough oxygen. The
most common symptom of angina is chest pain or discomfort.
About chronic heart failure :
Chronic heart failure is a heart disease which happens when your heart
cannot pump enough blood to
the rest of your body. The most common s
                                
                                Leggi il documento completo
                                
                            

Scheda tecnica

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Corlentor 5 mg film-coated tablets
Corlentor 7.5 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Corlentor 5 mg film-coated tablets
Each film-coated tablet contains 5 mg ivabradine (as hydrochloride).
_Excipient with known effect:_
Each film-coated tablet contains 63.91 mg lactose monohydrate.
Corlentor 7.5 mg film-coated tablets
Each film-coated tablet contains 7.5 mg ivabradine (as hydrochloride).
_Excipient with known effect:_
Each film-coated tablet contains 61.215 mg lactose monohydrate.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet.
Corlentor 5 mg film-coated tablets
Salmon-coloured, oblong, film-coated tablet scored on both sides,
engraved with “5” on one face
and
on the other face.
The tablet can be divided into equal doses.
Corlentor 7.5 mg film-coated tablets
Salmon-coloured, triangular, film-coated tablet engraved with
“7.5” on one face and
on the other
face.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Symptomatic treatment of chronic stable angina pectoris
Ivabradine is indicated for the symptomatic treatment of chronic
stable angina pectoris in coronary
artery disease adults with normal sinus rhythm and heart rate ≥ 70
bpm. Ivabradine is indicated :
-
in adults unable to tolerate or with a contraindication to the use of
beta-blockers
-
or in combination with beta-blockers in patients inadequately
controlled with an optimal beta-
blocker dose.
Treatment of chronic heart failure
3
Ivabradine is indicated in chronic heart failure NYHA II to IV class
with systolic dysfunction, in adult
patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in
combination with standard therapy
including beta-blocker therapy or when beta-blocker therapy is
contraindicated or not tolerated (see
section 5.1).
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Symptomatic treatment of chronic stable angina pectoris _
It is recommended that the decision to ini
                                
                                Leggi il documento completo
                                
                            

Documenti in altre lingue

Foglio illustrativo Foglio illustrativo bulgaro 12-10-2021
Scheda tecnica Scheda tecnica bulgaro 12-10-2021
Foglio illustrativo Foglio illustrativo spagnolo 12-10-2021
Scheda tecnica Scheda tecnica spagnolo 12-10-2021
Relazione pubblica di valutazione Relazione pubblica di valutazione spagnolo 25-02-2019
Foglio illustrativo Foglio illustrativo ceco 12-10-2021
Scheda tecnica Scheda tecnica ceco 12-10-2021
Foglio illustrativo Foglio illustrativo danese 12-10-2021
Scheda tecnica Scheda tecnica danese 12-10-2021
Foglio illustrativo Foglio illustrativo tedesco 12-10-2021
Scheda tecnica Scheda tecnica tedesco 12-10-2021
Foglio illustrativo Foglio illustrativo estone 12-10-2021
Scheda tecnica Scheda tecnica estone 12-10-2021
Foglio illustrativo Foglio illustrativo greco 12-10-2021
Scheda tecnica Scheda tecnica greco 12-10-2021
Foglio illustrativo Foglio illustrativo francese 12-10-2021
Scheda tecnica Scheda tecnica francese 12-10-2021
Relazione pubblica di valutazione Relazione pubblica di valutazione francese 25-02-2019
Foglio illustrativo Foglio illustrativo italiano 12-10-2021
Scheda tecnica Scheda tecnica italiano 12-10-2021
Relazione pubblica di valutazione Relazione pubblica di valutazione italiano 25-02-2019
Foglio illustrativo Foglio illustrativo lettone 12-10-2021
Scheda tecnica Scheda tecnica lettone 12-10-2021
Foglio illustrativo Foglio illustrativo lituano 12-10-2021
Scheda tecnica Scheda tecnica lituano 12-10-2021
Foglio illustrativo Foglio illustrativo ungherese 12-10-2021
Scheda tecnica Scheda tecnica ungherese 12-10-2021
Relazione pubblica di valutazione Relazione pubblica di valutazione ungherese 25-02-2019
Foglio illustrativo Foglio illustrativo maltese 12-10-2021
Scheda tecnica Scheda tecnica maltese 12-10-2021
Foglio illustrativo Foglio illustrativo olandese 12-10-2021
Scheda tecnica Scheda tecnica olandese 12-10-2021
Relazione pubblica di valutazione Relazione pubblica di valutazione olandese 25-02-2019
Foglio illustrativo Foglio illustrativo polacco 12-10-2021
Scheda tecnica Scheda tecnica polacco 12-10-2021
Foglio illustrativo Foglio illustrativo portoghese 12-10-2021
Scheda tecnica Scheda tecnica portoghese 12-10-2021
Relazione pubblica di valutazione Relazione pubblica di valutazione portoghese 25-02-2019
Foglio illustrativo Foglio illustrativo rumeno 12-10-2021
Scheda tecnica Scheda tecnica rumeno 12-10-2021
Foglio illustrativo Foglio illustrativo slovacco 12-10-2021
Scheda tecnica Scheda tecnica slovacco 12-10-2021
Relazione pubblica di valutazione Relazione pubblica di valutazione slovacco 25-02-2019
Foglio illustrativo Foglio illustrativo sloveno 12-10-2021
Scheda tecnica Scheda tecnica sloveno 12-10-2021
Foglio illustrativo Foglio illustrativo finlandese 12-10-2021
Scheda tecnica Scheda tecnica finlandese 12-10-2021
Relazione pubblica di valutazione Relazione pubblica di valutazione finlandese 25-02-2019
Foglio illustrativo Foglio illustrativo svedese 12-10-2021
Scheda tecnica Scheda tecnica svedese 12-10-2021
Foglio illustrativo Foglio illustrativo norvegese 12-10-2021
Scheda tecnica Scheda tecnica norvegese 12-10-2021
Foglio illustrativo Foglio illustrativo islandese 12-10-2021
Scheda tecnica Scheda tecnica islandese 12-10-2021
Foglio illustrativo Foglio illustrativo croato 12-10-2021
Scheda tecnica Scheda tecnica croato 12-10-2021

Cerca alert relativi a questo prodotto

Visualizza cronologia documenti